X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8712) 8712
Publication (627) 627
Newsletter (227) 227
Book Review (116) 116
Magazine Article (56) 56
Newspaper Article (41) 41
Dissertation (38) 38
Book Chapter (27) 27
Conference Proceeding (16) 16
Trade Publication Article (8) 8
Web Resource (4) 4
Data Set (2) 2
Transcript (2) 2
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronate (6145) 6145
humans (5349) 5349
female (4365) 4365
osteoporosis (4305) 4305
index medicus (3321) 3321
aged (2483) 2483
middle aged (2448) 2448
male (2211) 2211
endocrinology & metabolism (2128) 2128
bisphosphonates (2120) 2120
alendronate - therapeutic use (1779) 1779
bone density conservation agents - therapeutic use (1711) 1711
postmenopausal women (1636) 1636
animals (1633) 1633
bone density - drug effects (1551) 1551
osteoporosis - drug therapy (1465) 1465
fractures (1461) 1461
osteoporosis, postmenopausal - drug therapy (1382) 1382
orthopedics (1367) 1367
women (1362) 1362
bone density (1203) 1203
diphosphonates - therapeutic use (1167) 1167
bone-mineral density (1116) 1116
postmenopausal osteoporosis (1105) 1105
aged, 80 and over (1087) 1087
risk (1068) 1068
risk factors (1045) 1045
bones (947) 947
bone density conservation agents - adverse effects (926) 926
bone density conservation agents - administration & dosage (925) 925
bisphosphonate (913) 913
alendronate - administration & dosage (908) 908
drug therapy (906) 906
rats (898) 898
therapy (894) 894
risedronate (866) 866
rheumatology (854) 854
medicine & public health (852) 852
treatment outcome (851) 851
alendronate - pharmacology (847) 847
medicine, general & internal (841) 841
adult (831) 831
prevention (829) 829
density (804) 804
alendronate - adverse effects (775) 775
bone mineral density (753) 753
vertebral fractures (753) 753
zoledronic acid (744) 744
bone (735) 735
diphosphonates - administration & dosage (714) 714
diphosphonates - adverse effects (701) 701
health aspects (689) 689
pharmacology & pharmacy (688) 688
research (680) 680
care and treatment (663) 663
bone density conservation agents - pharmacology (633) 633
analysis (607) 607
endocrinology (583) 583
mineral density (569) 569
diphosphonates - pharmacology (554) 554
time factors (548) 548
fractures, bone - prevention & control (531) 531
in-vitro (508) 508
diphosphonates (500) 500
hip fracture (498) 498
etidronic acid - analogs & derivatives (496) 496
surgery (490) 490
fracture (489) 489
bone remodeling - drug effects (488) 488
randomized-trial (479) 479
administration, oral (468) 468
mice (456) 456
double-blind method (451) 451
drug administration schedule (450) 450
risedronate sodium (444) 444
absorptiometry, photon (436) 436
bone and bones - drug effects (431) 431
dentistry, oral surgery & medicine (424) 424
dosage and administration (419) 419
phosphonates (415) 415
denosumab (404) 404
teriparatide (404) 404
turnover (404) 404
retrospective studies (403) 403
pamidronate (393) 393
abridged index medicus (386) 386
dose-response relationship, drug (386) 386
resorption (386) 386
double-blind (384) 384
etidronic acid - therapeutic use (383) 383
parathyroid-hormone (378) 378
radiography (375) 375
osteoporosis - complications (374) 374
medicine, research & experimental (373) 373
follow-up studies (371) 371
trial (365) 365
hormone replacement therapy (362) 362
biochemical markers (361) 361
dentistry (360) 360
osteoporosis - prevention & control (350) 350
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8350) 8350
German (155) 155
Spanish (108) 108
Japanese (92) 92
French (68) 68
Portuguese (59) 59
Korean (51) 51
Chinese (47) 47
Turkish (31) 31
Italian (24) 24
Russian (22) 22
Norwegian (19) 19
Polish (17) 17
Danish (10) 10
Czech (6) 6
Slovak (6) 6
Croatian (5) 5
Dutch (5) 5
Hungarian (4) 4
Swedish (4) 4
Finnish (2) 2
Persian (2) 2
Serbian (2) 2
Slovenian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 08/2019, Volume 144, Issue 2, p. 416
for the AsthmaNet Investigators Loss of bronchoprotection (LOBP) with a regularly used long-acting [beta].sub.2-adrenergic receptor agonist (LABA) is well... 
Alendronate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 12, pp. 1189 - 1199
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
02/2013
Background: Osteoporosis is a chronic disease characterized by a decrease in bone mineral density (BMD) and corruption of the microarchitectural structure of... 
Methylprednisolon | Osteoporosis | Ovariectomy | Alendronate | Metyrosine
Web Resource
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 15, pp. 3795 - 3806
Abstract Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that... 
Advanced Basic Science | Dentistry | Angiogenesis | Dendrimers | PEG | Bone targeting | Alendronate | Polymer therapeutics | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PACLITAXEL | MACROMOLECULAR THERAPEUTICS | BISPHOSPHONATES | ANTICANCER | HIGH-RISK | PROSTATE-CANCER | AGENTS | DRUG-DELIVERY SYSTEMS | Neovascularization, Physiologic - drug effects | Paclitaxel - pharmacology | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Humans | Bone Neoplasms - secondary | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Tibia - pathology | Alendronate - chemistry | Alendronate - therapeutic use | Paclitaxel - chemistry | Human Umbilical Vein Endothelial Cells - cytology | Micelles | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Alendronate - pharmacokinetics | Tissue Distribution - drug effects | Human Umbilical Vein Endothelial Cells - drug effects | Treatment Outcome | Antineoplastic Agents - chemistry | Tibia - drug effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Xenograft Model Antitumor Assays | Animals | Fluorescein-5-isothiocyanate | Breast Neoplasms - pathology | Alendronate - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Ethylene glycol | Care and treatment | Phosphonates | Paclitaxel | Aluminum compounds | Fluorescence | Breast cancer | Metastasis | Drug therapy | Cancer | Index Medicus | Drugs | Imaging | Breast | Bones | Conjugation | Tumors
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 08/2010, Volume 25, Issue 8, pp. 1886 - 1894
Journal Article
Clinical calcium, ISSN 0917-5857, 2009, Volume 19, Issue 7, pp. 970 - 975
Journal Article
Osteoporosis International, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 317 - 326
The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent... 
Adherence | Persistence | Medicine & Public Health | Alendronate | Compliance | Orthopedics | Gynecology | Rheumatology | Denosumab | Endocrinology | MEDICATION | FRACTURE RATES | OSTEOPOROSIS | LOW BONE MASS | THERAPY | INJECTION | PATIENT PREFERENCE | ENDOCRINOLOGY & METABOLISM | BELIEFS | QUESTIONNAIRE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Alendronate - therapeutic use | Antibodies, Monoclonal, Humanized | Injections, Subcutaneous | Female | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Patient Preference | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Cross-Over Studies | Alendronate - adverse effects | Bone Density - drug effects | Medication Adherence | RANK Ligand - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Patient compliance | Research | Clinical trials | Comparative studies | Drug therapy | Womens health | Alendronic acid | Osteoporosis | Bone mineral density | Tablets | Bisphosphonates | Post-menopause | Original
Journal Article